Our Company
Xanamem^® (emestedastat)
Clinical Trials
Investor Centre
News
Contact Us

BACK TO NEWS

Therese Russell • 08 May 2019

Edison Investment Research
Phase II XanADu trial results

Enjoyed this read?

Stay up to date with our latest research.

Related articles

Press Releases and Media

A novel oral treatment for Alzheimer’s: Actinogen’s pivotal trial currently recruiting participants in the US

PR Newswire • July 22, 2025

Press Releases and Media

FIVEAA Adelaide radio interview with Dr Steven Gourlay on once-a-day Alzheimer’s pill [8m 25s]

FIVEAA • July 1, 2025

Press Releases and Media

Pill could halt Alzheimer’s – Potential ‘holy grail’ drug gets 100th patient for trial

Hobart Mercury • July 1, 2025

Our Company
Xanamem^® (emestedastat)

Clinical Trials

Investors
News
Contact Us
Target Market Determination

Copyright © 2025 Actinogen